

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

MERZ PHARMACEUTICALS, LLC and
MERZ NORTH AMERICA, INC.,

Plaintiffs,

v.

MSN PHARMACEUTICALS INC.

Defendant.

C.A. No. _____

COMPLAINT FOR PATENT INFRINGEMENT

Plaintiffs Merz Pharmaceuticals, LLC (“Merz LLC”) and Merz North America, Inc. (“Merz N.A.”) (together, “Merz” or “Plaintiffs”) bring this action against Defendant MSN Pharmaceuticals Inc. (“MSN”), and alleges as follows:

NATURE OF THE ACTION

1. This is an action for patent infringement of United States Patent Nos. 7,638,552 (“the ’552 Patent”) and 7,816,396 (“the ’396 Patent,” collectively, the “patents-in-suit”), arising under the United States patent laws, Title 35, United States Code. This action relates to MSN’s filing of Abbreviated New Drug Application (“ANDA”) No. 216084 under section 505(j) of the Federal Food, Drug and Cosmetic Act (“the Act”), 21 U.S.C. § 355(j), seeking United States Food and Drug Administration (“FDA”) approval to manufacture and sell a generic version of Plaintiffs’ CUVPOSA® (glycopyrrolate), 1mg/5mL oral solution (“CUVPOSA®”) prior to the expiration of the ’552 and the ’396 Patents.

2. By letter dated June 9, 2021, MSN notified Merz that MSN had filed ANDA No. 216084, seeking FDA approval to manufacture and sell a generic version of Merz's CUVPOSA®.

THE PARTIES

3. Merz LLC is a limited liability company organized and existing under the laws of North Carolina, with a principal place of business at 6501 Six Forks Road, Raleigh, North Carolina 27615. Merz LLC is in the business of, *inter alia*, researching, developing, manufacturing, marketing, promoting, selling, distributing, and/or obtaining regulatory approval for innovative pharmaceutical products throughout the United States, including in this judicial district.

4. Merz N.A. is a corporation organized and existing under the laws of the State of North Carolina, having a principal place of business at 6501 Six Forks Road, Raleigh, North Carolina 27615. Merz N.A. is in the business of, *inter alia*, researching, developing, manufacturing, marketing, promoting, selling, distributing, and/or obtaining regulatory approval for innovative pharmaceutical products throughout the United States, including in this judicial district.

5. On information and belief, MSN is a corporation that is incorporated in Delaware, having a principal place of business at 20 Duke Rd, Piscataway, NJ 08854.

6. On information and belief, MSN, by itself and/or through its affiliates and agents, is in the business of, *inter alia*, developing, manufacturing, and obtaining regulatory approval of generic copies of branded pharmaceutical products for distribution and sale throughout the United States, including within the State of Delaware.

7. On information and belief, MSN has filed ANDA No. 216084 and will be involved in the manufacture, importation, marketing and sale of the drug that is subject to ANDA No. 216084 if it is approved.

JURISDICTION AND VENUE

8. This Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331, 1338(a), 2201 and 2202.

9. This Court has personal jurisdiction over MSN for purposes of this civil action because, *inter alia*, MSN, on information and belief, is incorporated in the State of Delaware.

10. This Court also has personal jurisdiction over MSN for purposes of this civil action because, *inter alia*, MSN has filed ANDA No. 216084 and intends to make, use, offer for sale, sell and/or import its proposed ANDA product in the United States, including Delaware, prior to the expiration of the patents-in-suit if ANDA No. 216084 is approved. Such acts will lead to foreseeable harm to Plaintiffs in Delaware.

11. On information and belief, MSN has not challenged personal jurisdiction in this Court in one or more prior cases arising out of the filing of its ANDAs. *See, e.g., Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. et al.*, C.A. No. 21-283 (D. Del.); *Otsuka Pharmaceutical Co., Ltd. et al. v. MSN Laboratories Pvt. Ltd. et al.*, C.A. No. 20-1428 (D. Del.).

12. On information and belief, MSN has previously submitted to the jurisdiction of this Court and has availed itself of the legal protections of the State of Delaware, having asserted counterclaims in this jurisdiction. *See, e.g., Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc. et al.* C.A. No. 21-283 (D. Del.); *Otsuka Pharmaceutical Co., Ltd. et al. v. MSN Laboratories Pvt. Ltd. et al.*, C.A. No. 20-1428 (D. Del.).

13. Venue is proper in this Court pursuant to 28 U.S.C. §§ 1391 and 1400(b).

THE PATENTS-IN-SUIT AND CUVPOSA®

14. On December 29, 2009, the United States Patent and Trademark Office (“PTO”) issued the ’552 Patent, entitled “Method for Increasing The Bioavailability of Glycopyrrolate,” to Sciele Pharma, Inc., the initial assignee of the named inventors, Alan Roberts and Balaji Venkataraman. The ’552 Patent was subsequently assigned to Shiongi Pharma, Inc. on January 11, 2010; to Shionogi Inc. on March 31, 2011; and then to Merz LLC on August 24, 2012. Merz LLC is the current record owner of the ’552 Patent. A copy of the ’552 Patent is attached hereto as **Exhibit A**.

15. On October 19, 2010, the PTO issued the ’396 Patent, entitled “Method for Increasing The Bioavailability of Glycopyrrolate,” to Sciele Pharma, Inc., the initial assignee of the named inventors, Alan Roberts and Balaji Venkataraman. The ’396 Patent was subsequently assigned to Shiongi Pharma, Inc. on January 11, 2010; to Shionogi Inc. on March 31, 2011; and then to Merz LLC on August 24, 2012. Merz LLC is the current record owner of the ’396 Patent. A copy of the ’396 Patent is attached hereto as **Exhibit B**.

16. On July 28, 2010, the FDA approved New Drug Application (“NDA”) No. 022571 for CUVPOSA®. Merz LLC is the holder of NDA No. 022571 for CUVPOSA®.

17. In FDA’s publication entitled *Approved Drug Products with Therapeutic Equivalence Evaluations* (known as the “Orange Book”), the patents-in-suit are listed as covering CUVPOSA®.

DEFENDANT’S ANDA

18. On information and belief, MSN reviewed the patents-in-suit and certain commercial and economic information relating to CUVPOSA®, including estimates of the

revenues generated by the sale of CUVPOSA®, and decided to file an ANDA, seeking approval to market a glycopyrrolate oral solution.

19. On information and belief, MSN submitted to the FDA ANDA No. 216084 seeking approval to engage in the commercial manufacture, use, and sale of glycopyrrolate oral solution, prior to the expiration of the patents-in-suit.

20. On information and belief, MSN will manufacture, sell, market, and/or distribute a glycopyrrolate oral solution upon FDA approval of ANDA No. 216084.

21. Merz LLC received a letter dated June 9, 2021 from MSN notifying Merz LLC that ANDA No. 216084 includes “a certification pursuant to 21 U.S.C. § 355(j)(2)(B)(vii)(IV), [sic] that the ’552 and ’396 patents are invalid, unenforceable and/or will not be infringed by the manufacture, use, or sale of the product” described in ANDA No. 216084 (the “Paragraph IV certification”).

22. Plaintiffs commenced this action within 45 days of the date it received MSN’s notice of ANDA No. 216084 containing the Paragraph IV certification.

FIRST CLAIM FOR RELIEF
(Infringement of the ’552 Patent by MSN)

23. Plaintiffs repeat and reallege each and every allegation contained in paragraphs 1 through 22 hereof, as if fully set forth herein.

24. Through the conduct alleged above, MSN has infringed, and continues to infringe, one or more claims of the ’552 Patent.

25. By filing ANDA No. 216084 and seeking FDA approval to engage in the commercial manufacture, use, sale, marketing, distribution, and/or importation of the glycopyrrolate oral solution disclosed therein prior to the expiration of the ’552 Patent, MSN has infringed the ’552 Patent under 35 U.S.C. § 271(e)(2)(A).

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.